BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 37395949)

  • 1. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.
    Hayek OE; Rais-Bahrami S; McDonald A; Galgano SJ
    Curr Urol Rep; 2023 Oct; 24(10):471-476. PubMed ID: 37395949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy.
    Gawish A; Walke M; Röllich B; Ochel HJ; Brunner TB
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3937-3949. PubMed ID: 36029331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
    Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
    Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
    Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
    Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline.
    Vogel MME; Düsberg M; Stöhrer L; Dewes S; Sage EK; Borm KJ; Gschwend JE; Eiber M; Combs SE; Schiller K
    Eur Urol Oncol; 2022 Dec; 5(6):668-676. PubMed ID: 36280446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
    Francolini G; Banini M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Roghi M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L
    Prostate; 2023 Sep; 83(12):1201-1206. PubMed ID: 37290915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.
    Rischke HC; Eiberger AK; Volegova-Neher N; Henne K; Krauss T; Grosu AL; Jilg CA
    Adv Med Sci; 2016 Sep; 61(2):212-218. PubMed ID: 26895459
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
    Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
    Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.